( March 4, 2026, 12:14 PM EST) -- SAN FRANCISCO — A federal judge in California granted a biopharmaceutical company’s motion to dismiss investors’ amended class action against it for allegedly failing to disclose the findings from clinical trials of its lead product candidate that, once revealed, caused the company’s stock to drop, finding that the investors had repackaged arguments that had previously been rejected....